Attendee search 

We are a Nordic law firm with a simple business concept : to create value for you. This is the guiding principle in everything we do. This means that we always look for solutions which not only comply with the law, but which also generate commercial advantages. It also means that it's not enough for us to obtain results. We want good results. Irrespective of the industry. Irrespective of which Nordic country is involved. Cross-border.

The business operations conducted within life science companies often involve major risks and opportunities for significant earnings. The risks come not only from the advanced scientific and supervisory environment but also from complicated business models. A key to success is for companies to be able to handle these risks. This demands that the contracts which are produced exhaustively govern all of the risks and that these risks are appropriately allocated between the parties.

NORDIA has a practice group with lawyers experienced in life science to assist national and international companies in the area, both listed companies and private companies.

We are a Nordic law firm with a simple business concept : to create value for you. This is the guiding principle in everything we do. This means that we always look for solutions which not only comply with the law, but which also generate commercial advantages. It also means that it's not enough for us to obtain results. We want good results. Irrespective of the industry. Irrespective of which Nordic country is involved. Cross-border.

The business operations conducted within life science companies often involve major risks and opportunities for significant earnings. The risks come not only from the advanced scientific and supervisory environment but also from complicated business models. A key to success is for companies to be able to handle these risks. This demands that the contracts which are produced exhaustively govern all of the risks and that these risks are appropriately allocated between the parties.

NORDIA has a practice group with lawyers experienced in life science to assist national and international companies in the area, both listed companies and private companies.

• Dan Peters has >20 years of experience in pharmaceutical discovery and
  development as a key scientific and management leader at NeuroSearch A/S
• PET is a nuclear medicine technique for non-invasive, real-time 3D-imaging
  of physiological processes in the brain and other organs
• Development of best-in-class nicotinic alpha-7 PET ligands (11C-NS14492 and 18F-NS10743)
• 11C-NS14492 and 18F-NS10743 have potential for guiding diagnosis and treatment of Alzheimer’s Disease (Psychopharmacology (2006), 188(4), 509-520)
• High quality NET-PET ligands (11C-NS8880 and 18F-NS12137)
• SERT–PET ligands (11C-NS6417, 11C-NS9531 and 11C-NS9762)
• Broad IP portfolio within several classes with major focus on the EU and US-market
• DanPET owns IP-rights for the ligands mentioned above

Organ and cell transplantations are currently the standard therapy for end-stage organ failure. However, allograft rejections, monitoring of optimal immunosuppression, and shortage of donor organs, are major problems encountered in the field.

The Sahlgrenska Transplantation Unit which is the largest organ transplant clinic in Sweden, has in 2008 made strategic recruitments of a multi-disciplinary team of highly qualified and experienced transplant surgeons and research scientists who, in close collaboration with the clinical transplantation programs, have established the Laboratory for Transplantation and Regenerative Medicine at the Sahlgrenska Academy.

The various projects we present concern:

1) Prevention of allograft rejection by improved donor-recipient selection.
2) Solve organ shortage using two new strategies - namely to avoid allograft rejection by the creation of non-immunogenic scaffolds both for allo- and xenograft rejection and the generation of endothelial and hepatic progenitor cells for transplantation.

We have introduced new specific methods to characterize and assess the importance of alloantibodies, both HLA and non-HLA-specific, as a risk factor for graft rejections. Our efforts aiming at understanding the molecular basis of xenograft rejection will continue, but will focus on delineating the immunogenicity of vascular scaffolds (vessels and heart valves) derived from pig. Such scaffolds may constitute an on-demand source of templates for tissue-engineered vascular grafts.
We have succeeded in isolating human endothelial and liver progenitor cells that not only self-proliferate ex vivo, but also functionally repopulate the damaged organs/tissues of mice with acutely injured organs.
Recently, we have been pioneering in the field of tissue-engineering, creating biocompatible blood vessels for clinical use. Experimental injury models will be used to study mechanisms of human progenitor cell migration, integration and engraftment in the injured tissues. Deciphering mechanisms of stem cell migration and engraftment will provide clinically relevant information that will make tissue repopulation with stem cells more feasible clinically. Tissue-engineered biocompatible tissues or organs using recipient’s autologous stem cells will be a major breakthrough in regenerative medicine and may help solve the organ shortage.